Document is current
Any future updates will be listed below
-
Authors
Hengeveld, Paul J. https://orcid.org/0000-0002-0070-138X
Veelken, Hendrik https://orcid.org/0000-0002-9108-3125
van Bergen, Cornelis A. M. https://orcid.org/0000-0001-6386-4517
Quinten, Edwin
Vervoordeldonk, Mischa Y. L.
Ismailzada, Wahija
Barendse, Rob S.
Dubois, Julie M. N.
van Oers, Marinus H. J.
Geisler, Christian H.
Kater, Arnon P. https://orcid.org/0000-0003-3190-1891
Westerweel, Peter E. https://orcid.org/0000-0002-0746-7039
Langerak, Anton W. https://orcid.org/0000-0002-2078-3220
Levin, Mark-David https://orcid.org/0000-0003-2139-3547
- License Information
-
More Information
Article History
Received: 29 November 2022
Revised: 12 June 2023
Accepted: 14 July 2023
First Online: 21 July 2023
Competing interests
: JMND has received research funding from Roche/Genentech. APK has received research grants from Abbvie, AstraZeneca, BMS, Janssen and Roche Genentech and has performed Adboard activities for Abbvie, BMS, Janssen, LAVA and Roche Genentech. AWL has received research funding via an unrestricted grant from Roche-Genentech and speaker-fees from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. The remaining authors declare no competing financial interests.
